In conclusion, we reported a patient with anti‐MDA5 antibody‐positive DM‐ILD and concluded for the first time that tofacitinib may be an option for anti‐MDA5 antibody‐positive conversion during maintenance therapy. This evidence concerns the gene IFIH1 and interstitial lung disease.